(0.02%) 5 071.63 points
(-0.11%) 38 461 points
(0.10%) 15 713 points
(0.04%) $82.84
(-0.54%) $1.644
(-0.41%) $2 328.90
(-0.61%) $27.20
(-1.11%) $912.60
(0.06%) $0.935
(0.83%) $10.99
(-0.06%) $0.803
(-0.93%) $92.32
Live Chart Being Loaded With Signals
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally...
Stats | |
---|---|
Today's Volume | 21.59M |
Average Volume | 13.02M |
Market Cap | 22.79B |
EPS | HKD0 ( 2024-03-29 ) |
Last Dividend | HKD0.0120 ( 2017-06-05 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -30.97 |
ATR14 | HKD0.0170 (0.16%) |
Volume Correlation
Genscript Biotech Corp Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Genscript Biotech Corp Correlation - Currency/Commodity
Genscript Biotech Corp Financials
Annual | 2023 |
Revenue: | HKD839.53M |
Gross Profit: | HKD409.55M (48.78 %) |
EPS: | HKD-0.0453 |
Q2 | 2023 |
Revenue: | HKD391.31M |
Gross Profit: | HKD175.05M (44.73 %) |
EPS: | HKD-0.0444 |
Q4 | 2022 |
Revenue: | HKD321.02M |
Gross Profit: | HKD128.56M (40.05 %) |
EPS: | HKD-0.0455 |
Q2 | 2022 |
Revenue: | HKD309.59M |
Gross Profit: | HKD168.50M (54.43 %) |
EPS: | HKD-0.0648 |
Financial Reports:
No articles found.
Genscript Biotech Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.0120 | 2017-06-05 |
Last Dividend | HKD0.0120 | 2017-06-05 |
Next Dividend | HKD0 | N/A |
Payout Date | 2017-06-21 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | HKD0.0120 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.28 | -- |
Div. Sustainability Score | 2.42 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.896 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2357.HK | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
1336.HK | Ex Dividend Junior | 2023-07-06 | Annually | 0 | 0.00% | |
0388.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
6198.HK | Ex Dividend Knight | 2023-06-08 | Annually | 0 | 0.00% | |
1890.HK | Ex Dividend Knight | 2023-08-04 | Annually | 0 | 0.00% | |
0916.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
0052.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
2866.HK | Ex Dividend Junior | 2023-07-06 | Sporadic | 0 | 0.00% | |
1461.HK | Ex Dividend Junior | 2023-06-20 | Sporadic | 0 | 0.00% | |
0543.HK | Ex Dividend Junior | 2023-05-17 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.114 | 1.500 | -2.27 | -3.41 | [0 - 0.5] |
returnOnAssetsTTM | -0.0282 | 1.200 | -0.940 | -1.127 | [0 - 0.3] |
returnOnEquityTTM | -0.0695 | 1.500 | -1.884 | -2.83 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.76 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.12 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.92 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.246 | -1.500 | 5.90 | -8.85 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.144 | 2.00 | -0.0480 | -0.0959 | [0 - 30] |
freeCashFlowPerShareTTM | -0.273 | 2.00 | -0.136 | -0.273 | [0 - 20] |
debtEquityRatioTTM | 0.599 | -1.500 | 7.60 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.488 | 1.000 | 5.20 | 5.20 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.495 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.344 | 1.000 | -3.02 | -3.02 | [0.2 - 2] |
assetTurnoverTTM | 0.248 | 0.800 | -1.681 | -1.345 | [0.5 - 2] |
Total Score | 2.42 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -28.79 | 1.000 | -3.01 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0695 | 2.50 | -1.211 | -2.83 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.273 | 2.00 | -0.0909 | -0.273 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.144 | 2.00 | -0.0480 | -0.0959 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 70.81 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.342 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -0.631 |
Genscript Biotech Corp
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators